Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Olfson

Showing results (181-190 of 683) with videos related to

Pageof 69
Sort By:
Pharmacoepidemiology and Drug Safety|February 7, 2019
Misuse of prescribed opioids in the United StatesRamin Mojtabai, Masoumeh Amin-Esmaeili, Eleeka Nejat, et al.
JAMA|January 22, 2020
Trends in Buprenorphine Treatment in the United States, 2009-2018Mark Olfson, Victoria Shu Zhang, Michael Schoenbaum, et al.
Psychiatric Services (Washington, D.C.)|March 18, 2021
Changes in Buprenorphine Treatment After Medicaid ExpansionMark Olfson, Victoria Shu Zhang, Marissa King, et al.
Anesthesia and Analgesia|February 16, 2021
In ResponseCaleb Ing, Melanie M Wall, Mark Olfson, et al.
Journal of Affective Disorders|January 18, 2006
Health-related quality of life following ECT in a large community sampleW Vaughn McCall, Joan Prudic, Mark Olfson, et al.
The Journal of Clinical Psychiatry|February 20, 2013
Trends in office-based treatment of adults with stimulants in the United StatesMark Olfson, Carlos Blanco, Shuai Wang, et al.
The Journal of Clinical Psychiatry|February 24, 2026
Trends in Benzodiazepine Prescribing to Adults in the United States: Results From the Medical Expenditure Panel SurveyMark Olfson, Chandler McClellan, Samuel H Zuvekas, et al.
Journal of Substance Abuse Treatment|October 25, 2018
Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrolleesHillary Samples, Arthur Robin Williams, Mark Olfson, et al.
JAMA Network Open|July 27, 2019
Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity DisorderRyan S Sultan, Shuai Wang, Stephen Crystal, et al.
Psychiatric Services (Washington, D.C.)|September 30, 2021
Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United StatesNatalie Bareis, Mark Olfson, Melanie Wall, et al.
Pageof 69

Showing results (181-190 of 683) with videos related to

Sort By:
Pageof 69
Pharmacoepidemiology and Drug Safety|February 7, 2019
Misuse of prescribed opioids in the United StatesRamin Mojtabai, Masoumeh Amin-Esmaeili, Eleeka Nejat, et al.
JAMA|January 22, 2020
Trends in Buprenorphine Treatment in the United States, 2009-2018Mark Olfson, Victoria Shu Zhang, Michael Schoenbaum, et al.
Psychiatric Services (Washington, D.C.)|March 18, 2021
Changes in Buprenorphine Treatment After Medicaid ExpansionMark Olfson, Victoria Shu Zhang, Marissa King, et al.
Anesthesia and Analgesia|February 16, 2021
In ResponseCaleb Ing, Melanie M Wall, Mark Olfson, et al.
Journal of Affective Disorders|January 18, 2006
Health-related quality of life following ECT in a large community sampleW Vaughn McCall, Joan Prudic, Mark Olfson, et al.
The Journal of Clinical Psychiatry|February 20, 2013
Trends in office-based treatment of adults with stimulants in the United StatesMark Olfson, Carlos Blanco, Shuai Wang, et al.
The Journal of Clinical Psychiatry|February 24, 2026
Trends in Benzodiazepine Prescribing to Adults in the United States: Results From the Medical Expenditure Panel SurveyMark Olfson, Chandler McClellan, Samuel H Zuvekas, et al.
Journal of Substance Abuse Treatment|October 25, 2018
Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrolleesHillary Samples, Arthur Robin Williams, Mark Olfson, et al.
JAMA Network Open|July 27, 2019
Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity DisorderRyan S Sultan, Shuai Wang, Stephen Crystal, et al.
Psychiatric Services (Washington, D.C.)|September 30, 2021
Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United StatesNatalie Bareis, Mark Olfson, Melanie Wall, et al.
Pageof 69